FDA-Approved Medications to Treat Tardive Dyskinesia
Clicks: 138
ID: 119971
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
138 views
30 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #151 of 273 articles by views in the journal of clinical psychiatry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Follow along as expert Joseph P. McEvoy, MD, reviews the evidence.
| Reference Key |
mcevoy2019thefda-approved
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Joseph P. McEvoy; |
| Journal | the journal of clinical psychiatry |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.